S1 Table -

Whiteley, William N.; Ip, Samantha; Cooper, Jennifer A.; Bolton, Thomas; Keene, Spencer; Walker, Venexia; Denholm, Rachel; Akbari, Ashley; Omigie, Efosa; Hollings, Sam; Di Angelantonio, Emanuele; Denaxas, Spiros; Wood, Angela; Sterne, Jonathan A. C.; Sudlow, Cathie

doi:10.1371/journal.pmed.1003926.s003

pmed.1003926.s003.pdf (575.95 kB)

S1 Table -

journal contribution

posted on 2022-02-22, 19:01 authored by William N. Whiteley, Samantha Ip, Jennifer A. Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, Emanuele Di Angelantonio, Spiros Denaxas, Angela Wood, Jonathan A. C. Sterne, Cathie Sudlow

Estimates for (a) age-stratified risk of venous and arterial events during follow-up; (b) age-stratified incidence of events pre- and post-first ChAdOx1-S; (c) age-stratified incidence of events pre- and post-first BNT162b2; (d) age- and sex-stratified HR of events 1–28 and >28 days post-ChAdOx1-S vaccine; and (e) age- and sex-stratified HR of events 1–28 and >28 days post-ChAdOx1-S vaccine BNT162b2 vaccine. HR, hazard ratio.

(PDF)

History

Usage metrics

Keywords

positive predictive value coded healthcare data also prespecified adjustment 18 march 2021 deep vein thrombosis coronavirus disease 2019 lipid lowering medication based cohort study approximately 21 million 46 %) adults ci ): 138 8 december 2020 46 million adults intracranial venous thrombosis estimated incidence rates crude incidence rates xlink "> rates xlink "> thromboses 79 %) white 5 %) black first vaccination dose 28 days post population cohort study 1 %) asian ≥ 70 years england venous thrombotic events either vaccine compared 3 per million thrombocytopenic outcomes 1 19 vaccines chadox1 xlink ">either vaccine 5 million venous thrombosis thrombotic events thrombocytopenic events 84 %)51 %)per 100 first vaccination coronavirus infection black british asian british adults living adults aged 28 days venous thromboses venous events vaccine chadox1 antiplatelet medication anticoagulant medication 7 million 6 million 39 million 36 million 23 million 2 %)major venous arterial thromboses unusual locations small compared pulmonary embolism primary reason precise estimates population level performed separately observed increases myocardial infarction measure outcome may lead main limitations level risks identify exposures hospital admission hazard ratios generally lower different types confidence interval 70 years 40 years 307 );291 ).269 );253 );237 );19 morbidity 000 person &# 8805

Licence

CC BY 4.0

S1 Table -

History

Usage metrics

Categories

Keywords

Licence

Exports